Associated Papers
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Hirsch P et al.
Blood Cancer Journal, 2024
38871702 (PubMed )
Supplement: 41408_2024_1078_MOESM1_ESM.pdf
Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.
Fournier E et al.
Leukemia, 2022
Select a paper to view details